Erasca (ERAS) Operating Expenses (2020 - 2026)
Erasca posted quarterly Operating Expenses of $187.9 million for Q1 2026, up 427.4% year-on-year from $35.6 million in Q1 2025, and up 476.34% on a QoQ basis from $32.6 million in Q4 2025.
Erasca (ERAS) has 7 years of Operating Expenses data on file, last reported at $187.9 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 427.4% year-over-year to $187.9 million; the trailing twelve-month figure through Mar 2026 stood at $293.2 million (up 66.24% YoY), and the FY2025 full-year result was $140.9 million, down 21.54% from the prior year.
- Operating Expenses for Q1 2026 stood at $187.9 million, up from $32.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $187.9 million in Q1 2026 and bottomed at $32.6 million in Q4 2025.
- The 5-year median for Operating Expenses is $36.5 million (2022), against an average of $52.8 million.
- The widest annual swing landed in 2023, when Operating Expenses sank 75.47%; it then surged 427.4% in 2026.
- A 5-year view of Operating Expenses shows it stood at $138.1 million in 2022, then tumbled by 75.47% to $33.9 million in 2023, then grew by 5.43% to $35.7 million in 2024, then fell by 8.7% to $32.6 million in 2025, then jumped by 476.34% to $187.9 million in 2026.
- The last three Operating Expenses figures came in at $187.9 million (Q1 2026), $32.6 million (Q4 2025), and $34.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 187.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187.91 Mn |
| Dec 31, 2025 | 32.60 Mn |
| Sep 30, 2025 | 34.55 Mn |
| Jun 30, 2025 | 38.13 Mn |
| Mar 31, 2025 | 35.63 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Sep 30, 2024 | 37.24 Mn |
| Jun 30, 2024 | 67.78 Mn |
| Mar 31, 2024 | 38.85 Mn |
| Dec 31, 2023 | 33.87 Mn |
| Sep 30, 2023 | 34.66 Mn |
| Jun 30, 2023 | 35.97 Mn |
| Mar 31, 2023 | 37.03 Mn |
| Dec 31, 2022 | 138.08 Mn |
| Sep 30, 2022 | 36.96 Mn |
| Jun 30, 2022 | 35.91 Mn |
| Mar 31, 2022 | 36.51 Mn |
| Dec 31, 2021 | 31.05 Mn |
| Sep 30, 2021 | 46.04 Mn |
| Jun 30, 2021 | 28.18 Mn |
| Mar 31, 2021 | 19.61 Mn |
| Dec 31, 2020 | 66.97 Mn |
| Sep 30, 2020 | 11.16 Mn |
| Jun 30, 2020 | 7.28 Mn |